Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Orexo Ab

Other

Novo Nordisk A/s

Dirk Stenkamp

Klaus Rudolf

Stephan Georg Mueller

Henri Doods

Philipp Lustenberger

Kirsten Arndt

Gerhard Schaenzle

Marco Santagostino

Marcus Schindler

Fabio Paleari

Roland Pfau

Raimund Kuelzer

Alexander Dreyer

Henning Priepke

Gerald Juergen Roth

Thorsten Lehmann-Lintz

Benjamin Pelcman

Dirk Gottschling

Annekatrin Charlotte Heimann

Robert Roenn

Leo Thomas

Georg Dahmann

Rudolf Hurnaus

Ralf Lotz

Juergen Mack

Eckhart Bauer

Ralf R H Lotz

Edgars Suna

Dimitrijs Lubriks

Knud Erik Andersen

Bernd Peschke

Klaus Klinder

Martin Lenter

Bernd Krist

Norbert Hauel

Kai Gerlach

Florencio Zaragoza Dorwald

Ulla Grove Sidelmann

Stephan Georg Muller

Armin Heckel

Thorsten K Oost

Joerg Kley

Ingrid Pettersson

Stefan Scheuerer

Birgitte Langer Eriksen

Bernd Nosse

Thomas Trieselmann

Heather Tye

Bradford S Hamilton

Alexander Heim-Riether

Florencio Zaragoza Dörwald

Birgitte Schjellerup Wulff

Alexander Heifetz

Juergen Prestle

Heike-Andrea Wieland

Birgitte Eriksen

Natacha Prevost

Stephan Georg Müller

Tine Krogh Jørgensen

Philip Lustenberger

Kristen Arndt

Stephan-Georg Mueller

Christopher John Brown

Ralf R Lotz

Gerald Jurgen Roth

Rudlof Klaus

Stephan-Georg Müller

Ralf Richard Hermann Lotz

Christoper John Brown

The present invention relates to compounds defined by formula I wherein the groups X, Y, W and Rto Rare defined as in claim, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.

6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them

There are provided compounds of formula (I), wherein R, R, R, Q, Q, Q, Q, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer. 

1H-benzimidazole-5-carboxamides as anti-inflammatory agents

This invention relates to compounds of formula I, their use as inhibitors of the microsomal prostaglandin Esynthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions such as inflammatory/nociceptive pain. A, M, R, R, R, R, R, Q, Q, Q, Z, Z, Z, Zand W have meanings given in the description.

Compounds

The present invention relates to the new compounds of general formula I wherein A, U, V, X, Y, R, Rand Rare defined as stated hereinafter, the tautomers, the isomers thereof, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.

Pyrimidine derivatives which are CGRP&#x2014;antagonists

Pyridone and pyridazinone derivatives that are active against the melanin-concentrating hormone (MCH) and useful as anti-obesity pharmaceuticals.

Pyridone and pyridazinone derivatives as anti-obesity agents

The present invention relates to compounds of general formula I in which A, L, M, Q, Q, Q, R, R, R, R, R, W, X, Y, Z, Z, Zare defined in the description, the salts thereof, particularly the physiologically acceptable salts thereof. The compounds are of potential utility in the treatment and/or prevention of inflammatory diseases and associated conditions, in particular, in the treatment and/or prevention of pain. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to their preparation.

1H-benz imidazole-5-carboxamides as anti-inflammatory agents

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R, R, Rand Rare defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.

This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin Esynthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R, R, R, R, Rhave meanings given in the description.

3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents

This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin Esynthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, L, M, W, R, R, R, R, R, R, R, R, Rhave meanings given in the description.

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R, Rand Rare defined as stated hereinafter, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

CGRP antagonists

The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, Rand Rhave the meanings given in claim. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin Esynthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R, R, R, Rhave meanings given in the description.

Inhibitors of the microsomal prostaglandin E2 synthase-1

This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin Esynthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, L, M, W, R, R, R, R, R, R, R, Rhave meanings given in the description.

This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin Esynthase-1 (mPGES-1), to pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R, R, R, R, R, R, R, R, R, R, Rhave meanings given in the description.

Growing community of inventors

Biberach, Germany

Dirk Stenkamp